Natalia Schutz

Natalia Schutz

Auto-generated profile, based on publicly available information

Natalia Schutz

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in JCO Global Oncology
Verified
Journal Article
Open access
HMHumberto Martinez-Cordero
Humberto Martinez-Cordero
CPCamila Peña
Camila Peña
NSNatalia Paola Schutz
Natalia Paola Schutz
VBVirginia Bove
Virginia Bove
FVFiorella Villano
Fiorella Villano
OMOn Behalf Of Gelamm (Grupo de Estudio Latinoamericano de Mieloma Múltiple)
On Behalf Of Gelamm (Grupo de Estudio Latinoamericano de Mieloma Múltiple)
PURPOSE: Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce. PATIENTS AND METHODS: We analyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MM age 40 years or younger compared with 256 patients age 41-50 years and 957 patients age 51 years or older. RESULTS: There were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Of the patients age 40 years or younger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival. CONCLUSION: In conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly.

20 March 2020 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
NSNatalia P. Schütz
Natalia P. Schütz
POPaola Ochoa
Paola Ochoa
PDPatricio Duarte
Patricio Duarte
GRGuillermina Remaggi
Guillermina Remaggi
SYSebastián Yantorno
Sebastián Yantorno
DFDorotea Fantl
Dorotea Fantl

13 March 2025 in Blood Advances
Verified
Journal Article
Open access
VHVania Hungria
Vania Hungria
RGRafael Gaiolla
Rafael Gaiolla
KGKenny Mauricio Galvez
Kenny Mauricio Galvez
GRGuillermina Remaggi
Guillermina Remaggi
NSNatalia Schutz
Natalia Schutz
DTDamila Cristina Trufelli
Damila Cristina Trufelli
Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged ≥18 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n = 339) and private (n = 682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio, 0.84; 95% confidence interval, 0.67-1.04; P = .109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. This trial was registered at www.clinicaltrials.gov as #NCT03955900.

5 September 2023 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
CSCristian Seehaus
Cristian Seehaus
NSNatalia Schutz
Natalia Schutz
EBErika Brulc
Erika Brulc
GFGonzalo Ferini
Gonzalo Ferini
JAJorge Arbelbide
Jorge Arbelbide
ABAna Lisa Basquiera
Ana Lisa Basquiera
Introduction: The treatment of elderly multiple myeloma (MM) patients with autologous stem cell transplantation (ASCT) is a controversial procedure. Most clinical trials evaluating the safety and efficacy of ASCT have primarily included patients younger than 65 years. Design and methods This was a retrospective analysis of patients with MM who underwent ASCT between 2008 and 2018. Patients at or over 65 years were compared with patients under 65 years. We analyzed treatment-related mortality (TRM), response rate, progression-free survival (PFS) and overall survival (OS). Results: Two hundred and twenty-one patients were included: 50 patients at or over 65 years, (median age 68 years), including 7 patients over 70 years and 151 patients under 65 years, (median age 57 years). No differences were found in the neutrophil and platelet engraftment, median days of hospitalization and life support requirement during the hospitalization period for the ASCT. No statistically significant differences were found in the incidence of TRM between both groups at 100 days post-transplant (2% vs. 2.9%, p = 0.322). The ASCT improved complete response and stringent complete response rates (44% vs. 37%, p < 0.001). Survival was not modified by age: after a median follow-up of 53 months, the estimated PFS rates at three years were 63% and 60% (p = 0.88) and the OS rates at five years were 75% and 74% (p = 0.72), respectively. Conclusions: Our data suggest that the ASCT is feasible in selected elderly patients with MM over 65 years of age, achieving response and survival rates similar to those of younger patients.

15 April 2025 in International Journal of Hematology
Verified
Journal Article
Open access
PDF file
KKKihyun Kim
Kihyun Kim
EVEstelle Verburgh
Estelle Verburgh
TMTatiana Mitina
Tatiana Mitina
Wenming ChenWenming Chen
Wenming Chen
SYSu-Peng Yeh
Su-Peng Yeh
MBMeral Beksac
Meral Beksac
Background: Real-world data on multiple myeloma (MM) outside Europe and North America are limited. The INTEGRATE study retrospectively assessed real-world treatment pathways and outcomes in MM from Argentina, China, South Korea, South Africa, Russia, Saudi Arabia, Taiwan, and Türkiye. Methods: Medical records (2010–2011) of patients (≥ 18 years) with newly diagnosed MM were analyzed. The primary endpoint was time to next treatment (TTNT). Secondary endpoints included treatment pathways and clinical outcomes stratified by stem cell transplantation (SCT). Results: Of 1511 patients analyzed (median age: 59.5 years), 32% had IgG kappa MM and 35.9% had International Staging System stage III disease. Bortezomib- and thalidomide-based chemotherapy regimens were the most common first- and second-line treatments; lenalidomide-based regimens were common in later lines. Median TTNT from initiation of first-line treatment was 39.5 months. Only 31.7% of patients received SCT at diagnosis, with improved outcomes versus those without SCT (median overall survival: 114.1 vs 85.9 months; 5-year relapse-free rates after first-line treatment: 58.2% vs 49.3%). Conclusion: Treatment strategies for MM outside Europe and North America align with guideline recommendations. More effective treatments and SCT at treatment initiation are needed. This study can guide future research in these regions utilizing newer treatment options.

28 December 2021 in Medwave
Verified
Journal Article
Open access
MPMaría Lourdes Posadas-Martínez
María Lourdes Posadas-Martínez
FGFelipe Torres Gómez
Felipe Torres Gómez
DMDaniela Mezzarobba
Daniela Mezzarobba
NSNatalia Schutz
Natalia Schutz
JRJesica Ruberto
Jesica Ruberto
DGDiego Giunta
Diego Giunta
Objective We aim to evaluate factors associated with the recurrence of thromboembolic episodes among patients with a first episode of venous thromboembolic disease during anticoagulation treatment and at least one year after treatment suspension. Methods A prospective cohort of patients with a first episode of deep vein thrombosis confirmed by Doppler ultrasound and initiated anticoagulation treatment. Participants were registered in the Institutional Registry of Thromboembolic Disease between June 2015 and March 2019. Patients with cancer, with permanent inferior vena cava filter implant, and those who refused to participate or did not provide informed consent were excluded. All patients were evaluated within treatment at 30 days and at least one year after the suspension of anticoagulation with a D-dimer study and an ultrasound. All patients were evaluated for recurrence, bleeding (major and minor), and death. Results A total of 304 patients were recruited during the study period. Seventy-three percent were female, and the median age was 80 years. The rate of recurrence rate during anticoagulation treatment was 5% (N = 16/303; 95% confidence interval: 3 to 8), and 5% during post-suspension follow-up (N = 11/202; 95%CI: 3 to 9). The overall bleeding rate was 13% (N = 39; 95%CI: 9 to 17), and 5% for major bleeding. Patients who recurred had higher basal D-dimer mean, higher neutrophils and monocytes, and a higher prevalence of age-adjusted D-dimer ratio greater than 0.5 before discontinuation. In addition, they more frequently had complete leg involvement by ultrasound and received a shorter treatment. Conclusions Although some baseline and pre-suspension parameters had a higher recurrence incidence, statistical significance was not reached, probably due to small statistical power and a short-term follow-up.